A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes
Completed · Phase 3 · NCT03740919
Conditions: Type 1 Diabetes Mellitus
At a glance
- Research payments reported, 2025
- $11,632
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 751
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY900014 (drug), Insulin Lispro (drug), Insulin Glargine (drug), Insulin Degludec (drug)
- Dates
- Started 2019-04-07; completion 2021-07-02
- Results posted
- Yes
The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) in children and adolescents with type 1 diabetes (T1D).
From ClinicalTrials.gov, last updated 2022-01-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $11,632 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.